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ARTICLE
Lethal Contractural Syndrome Type 3 (LCCS3) Is Caused
by a Mutation in PIP5K1C, Which Encodes PIPKIg
of the Phophatidylinsitol Pathway
Ginat Narkis, Rivka Oﬁr, Daniella Landau, Esther Manor, Micha Volokita, Relly Hershkowitz,
Khalil Elbedour, and Ohad S. Birk
Lethal congenital contractural syndrome (LCCS) is a severe form of arthrogryposis. To date, two autosomal recessive
forms of the disease (LCCS and LCCS2) have been described and mapped to chromosomes 9q34 and 12q13, respectively.
We now describe a third LCCS phenotype (LCCS3)—similar to LCCS2 yet without neurogenic bladder. Using 10K single-
nucleotide–polymorphism arrays, we mapped the disease-associated gene to 8.8 Mb on chromosome 19p13. Further
analysis using microsatallite markers narrowed the locus to a 3.4-Mb region harboring 120 genes. Of these genes, 30
candidates were sequenced, which identiﬁed a single homozygous mutation in PIP5K1C. PIP5K1C encodes phosphati-
dylinositol-4-phosphate 5-kinase, type I, gamma (PIPKIg), an enzyme that phophorylates phosphatidylinositol 4-phos-
phate to generate phosphatidylinositol-4,5-bisphosphate (PIP2). We demonstrate that the mutation causes substitution
of aspartic acid with asparagine at amino acid 253 (D253N), abrogating the kinase activity of PIPKIg. Thus, a defect in
the phosphatidylinositol pathway leading to a decrease in synthesis of PIP2, a molecule active in endocytosis of synaptic
vesicle proteins, culminates in lethal congenital arthrogryposis.
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Arthrogryposis multiplex congenita (AMC) is a hetero-
geneous group of disorders characterized by congenital
nonprogressive joint contractures. It has a worldwide in-
cidence of 1 in 3,000, but it is more common in isolated
populations, such as Finland1 and the Bedouin commu-
nity in Israel. To date, four genetic loci associated with
autosomal recessive AMC syndromes have been described.
AMC, neurogenic type (AMCN [MIM 208100], on chro-
mosome 5q35), described in a large Israeli-Arab inbred
kindred, is a nonprogressivemultiple joint contracturedis-
ease that is not lethal.2,3 Arthrogryposis–renal dysfunc-
tion–cholestasis syndrome (ARC [MIM 208085], caused by
VPS33B mutations, on chromosome 15q26.14) is a neu-
rogenic AMC, with renal tubular dysfunction and neo-
natal cholestasis, that leads to death during the 1st year
of life.5–9 Lethal congenital contractural syndrome (LCCS
[MIM 253310], on chromosome 9q3410), reported in Fin-
land,11 is characterized by early fetal hydrops and akinesia,
the Pena-Shokeir phenotype, fractures, multiple pterygia,
and a speciﬁc neuropathology in the spinal cord.12,13
LCCS2 (MIM 607598) is prevalent in a large inbred Israeli-
Bedouin kindred.14 The phenotype, which is lethal during
the neonatal period inmost cases, is characterized bymul-
tiple joint contractures, micrognathia, anterior horn at-
rophy in the spinal cord, and a unique feature of a mark-
edly distended urinary bladder. Individuals affected with
LCCS2 lack the hydrops, pterygia, and multiple fractures
that are seen in LCCS. The LCCS2 phenotype suggests
a spinal cord neuropathic etiology.14 We have recently
mapped the LCCS2 locus to chromosome 12q13.15
We now describe a novel autosomal recessive LCCS
(type 3 [LCCS3]), similar to LCCS2 yet lacking the uro-
genic bladder defect. We mapped the genetic defect lead-
ing to this syndrome to 3.4 Mb on chromosome 19p13
and show that LCCS3 results from a mutation in PIP5K1C
(GenBank accession number NM_012398).
Patients and Methods
Patient Samples
The pedigree of extended family A is shown in ﬁgure 1. Four
affected and 23 unaffected individuals of the same consanguin-
eous Bedouin tribe were subject to genetic analysis. Another un-
related Bedouin family (ﬁg. 1B) presenting with an identical phe-
notype was also analyzed. Blood samples were obtained with
informed consent after approval was received from the Soroka
University Medical Center institutional review board. DNA was
isolated from whole blood, tissue samples, or cultured cells, with
use of the PUREGENE DNA Isolation Kit per the manufacturer’s
instructions (Gentra Systems).
Genetic Linkage Studies
Genomewide linkage analysis was undertaken on DNA samples
of four affected individuals and two parents, with use of the Af-
fymetrix GeneChip Human Mapping 10K Array Xba 142 2.0 ac-
cording to the Affymetrix GeneChip Mapping Assay protocol at
the biological services, Weizmann Institute of Science, Israel.
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Figure 1. Israeli-Bedouin kindreds affected with LCCS3. Blackened and unblackened symbols represent affected and unaffected in-
dividuals, respectively. Numbers denote individuals whose DNA samples were analyzed. A, Pedigree of family A. B, Pedigree of family
B.
GeneChip data analysis was done using the Genotyping Data
Analysis Software to obtain SNP genotyping, genotype calls,
marker orders, and map distance. An average of ∼11,500 SNPs for
each person was genotyped, with an average SNP call rate of
99.1%. The results were organized in Excel software. Fine map-
ping was performed using microsatellite markers within the in-
terval (listed in table 1) as follows: PCR products were separated
on a 6% polyacrylamide gel and were visualized by silver stain-
ing.15 Haplotypes were manually constructed and analyzed. Mi-
crosatellite markers were selected from public genome databases
(Marshﬁeld, Ge´ne´ton, and deCODE Genetic maps). Novel micro-
satellite markers were planned using the Tandem Repeats Finder
program and the University of California–Santa Cruz (UCSC) Ge-
nome Browser database and were designed using the Primer3 pro-
gram. Two-point linkage analysis was performed using SUPER-
LINK software.16
Sequence Analysis
Positional candidate genes were selected according to data in pub-
lic databases (National Center for Biotechnology Information
Map Viewer and UCSC Genome Browser). The coding sequences
were ampliﬁed from genomic DNA or cDNA with PCR primers
designed using the Primer3 program. RNA was extracted from
cultured ﬁbroblasts of affected individuals. PCR products were
subject to agarose-gel electrophoresis and gel extraction (QIA-
GEN), followed by sequencing with either the forward or reverse
primer on an ABI PRISM 377 DNA Sequencer (Applied Biosys-
tems). Results were analyzed using ChromasPro software, and the
obtained DNA sequences were compared with published se-
quences by use of BLAST. Primers used to amplify the coding
sequence of PIP5K1C from cDNA of patients with LCCS3 are listed
in table 2.
Screening for the G757A Mutation in PIP5K1C
Genomic DNA ﬂanking the G757A substitution was ampliﬁed
(PIP5K1C-ex7F primer, 5′-GCA GAA CCT CAA CCA GAA CC-3′,
and PIP5K1C-ex7R primer, 5′-GTC CTG CAT GAA GTC CAG GT-
3′). The G757A mutation in the PIP5K1C gene abolishes a TaqI
restriction site. Screening for the mutation was performed on the
basis of differential restriction products.
Construction of Expression Plasmids
Full-length cDNA of normal and mutant PIP5K1C from cul-
tured ﬁbroblasts were PCR cloned into pGEX-4T-1 vector (Life
Technologies), and the sequence was veriﬁed. Primers used
for PCR ampliﬁcation were 5′-AATTCATGGAGCTGGAGGTAC-
CGG-3′ (forward) and 5′-TCGAGTTATGTGTCGCTCTCGCCGT-3′
(reverse).
Expression and Puriﬁcation of the Recombinant GST-Fusion
Protein
Proteins were expressed in Origami B (DE3) Escherichia coli (Nov-
agen). In brief, overnight culture was diluted 1:100 and was
grown to optical density OD600 ∼0.6. Protein expression was in-
duced by the addition of 0.1 mM isopropyl b-D-1-thiogalacto-
pyranoside at 15C overnight. Cells were lysed (in 50 mM Tris-
HCl [pH 7.5], 150 mM NaCl, 0.1 mg/ml lysozyme, 20 mg DNase
I, and 0.1 M phenylmethylsulphonyl ﬂuoride) at 4C for 1 h and
were sonicated. Proteins were puriﬁed with glutathione agarose
beads (0.3 ml/liter of culture [Sigma]) for 1 h at 4C and were
eluted with 0.3 ml of 10-mM reduced glutathione (Sigma) in 50
mM Tris-HCl (pH 8.0).
PIP5K1C Kinase Activity Assay
The reaction was performed in a ﬁnal volume of 50 ml kinase
buffer containing 50mM Tris-HCl (pH 7.5), 1mM ethylene glycol
tetraacetic acid, 10 mM MgCl2, 80 mM phosphatidylinositol 4-
phosphate (PI4P) (Sigma), 50 mM ATP, 10 mCi of [g32P]ATP, and
0.4 mg of recombinant protein for 11 min at room temperature.
The reaction was stopped by adding 100 ml of 1-M HCl. Lipids
were extracted with 200 ml of chloroform/methanol (1:1) and
were separated using thin-layer chromatography plates (SilicaGel
60 [Merck]) in chloroform/methanol/NH4OH/H2O (90:90:7:22).
The labeled products were detected by autoradiography.17
Results
We describe a novel autosomal recessive LCCS, LCCS3,
that is prevalent in a large, inbred Israeli-Bedouinkindred,
with nine affected individuals identiﬁed to date (ﬁg. 1A).
The phenotype is similar to that of LCCS2 but lacks the
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Table 1. Genotyping of All Affected Individuals of Family A at the LCCS3 Chromosome 19
Locus
Physical
Map
Marshﬁeld Genetic
Map
Allele for Individual
Marker (kb) (cM) 7 8 11 14
D19S886 949,791 .00 4 4 4 4 1 4 1 4
D19S1166 3,026,947 9.84 2 4 4 4 4 4 1 4
D19S247 3,091,202 9.84 2 2 2 2 2 2 2 2
D19S120 3,131,343 10.97 … … … … 4 4 4 4
D19S424 3,177,373 … 5 5 5 5 5 5 5 5
rs2108389 3,542,590 … 2 2 2 2 2 2 2 2
Ch19_AAAT2 3,579,205 … 2 2 2 2 2 2 2 2
Ch19_GT 3,669,061 … 2 2 2 2 2 2 2 2
Ch19_AAAG 3,830,455 … 1 1 1 1 1 1 1 1
Ch19_CTTT 4,025,911 … 1 1 1 1 1 1 1 1
D19S894 4,343,434 15.55 2 2 2 2 2 2 2 2
D19S216 4,900,376 20.01 3 3 3 3 3 3 3 3
D19S549 5,443,422 20.01 2 2 2 2 2 2 2 2
rs1384936 5,374,643 … 1 1 1 1 1 1 1 1
D19S177 5,468,626 20.75 1 1 1 1 1 1 1 1
Ch19_ATTC 5,747,132 … 3 3 3 3 3 3 3 3
rs639251 5,913,530 … 2 2 2 2 2 2 2 2
D19S1034 6,064,482 20.75 1 1 1 1 1 1 1 1
D19S427 6,141,901 20.75 4 4 4 4 4 4 4 4
Ch19_GAAT 6,291,300 … 4 4 4 4 4 4 4 4
Ch19_CTAT 6,431,574 … 3 3 3 2 3 3 3 3
rs2241393 6,636,304 … 1 1 1 1 1 1 1 1
rs164022 6,779,040 … 2 2 2 2 2 2 2 2
Ch19_TTCC 6,848,927 … 5 4 4 4 4 4 4 4
D19S905 7,576,090 25.17 4 2 6 1 2 3 2 3
rs1862456 8,829,549 … 2 2 2 1 2 1 2 1
D19S391 8,524,703 28.83 5 5 5 1 5 6 5 6
NOTE.—The shaded region indicates the area of the shared homozygous region. Microsatellite markers
(ch19_AAAT2, ch19_GT, ch19_AAAG, ch19_CTTT, ch19_GAAT, ch19_CTAT, and ch19_TTCC) were designed using the
Tandem Repeats Finder program and the UCSC Genome Browser database.
Table 2. Primers Used for Sequencing the cDNA of
PIP5K1C
Primer
Primer Sequence
(5′r3′)
Forward Reverse
PIP5K1C_CDS1 GCCATGGAGCTGGAGGTA CTTGAGGTGCATCTTGACCA
PIP5K1C_CDS2 GCTGCTGCCCAAGTTCTATG AGGTCGTACTGGGCCTCCT
PIP5K1C_CDS3 TCATGAGCAACACGGTCTTT GCCGGAGCAGAAGTGGAG
urogenic bladder defect. The phenotype can be distin-
guished from the original LCCS by the absence of hydrops,
fractures, and multiple pterygia.
Detailed Clinical Phenotype of LCCS3
All affected newborns were small or borderline adequate
for gestational age. The limbs showed severemultiple joint
contractures with severe muscle wasting and atrophy,
mainly in the legs. Prenatal sonographic examination and
postnatal physical examination identiﬁed no additional
abnormal ﬁndings in any of the affected subjects (ﬁg. 2).
Four of the nine gestations with affected embryos were
terminated on the basis of ultrasonographic ﬁndings of
fetal akinesia and fetal limb contractures. The other ﬁve
subjects were born alive (two at 29 wk gestation and three
at term) and died of respiratory insufﬁciency minutes to
hours after birth. Karyotype, assayed for three of the sub-
jects, was normal. None of the families agreed to post-
mortem examination.
Homozygosity Mapping
Because the LCCS3 phenotype is similar to that of LCCS2,
we ﬁrst tested homozygosity of LCCS3-affected individ-
uals at the LCCS2 locus. Linkage to the 12q13 LCCS2 locus
was ruled out in the LCCS3-affected kindred—as was link-
age to any of the three other loci associated with auto-
somal recessive arthrogryposis (AMCN at 5q35,2,3 ARC at
15q26.1,4 and LCCS at 9q3410) (data not shown).
To identify the locus harboring the disease-causing
molecular defect, genomewide linkage analysis was per-
formed. DNA samples of all four available affected indi-
viduals (7, 8, 11, and 14) of family A (ﬁg. 1A) were tested
using the Affymetrix 10K SNP arrays. We developed Excel-
based software that allowed easy identiﬁcation of regions
of homozygosity; the results were organized according to
the location of the markers on the chromosomes andwere
labeled according to their genotype (in table 3, italics in-
dicate subjects homozygous for allele A, and bold type
indicates those homozygous for allele B). A function in
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Figure 2. LCCS3-affected fetus at 16 wk gestation
Table 3. Chromosome 19 Locus in LCCS3-Affected Family A—Linkage Analysis Results of the Affymetrix
GeneChip SNP Arrays
dbSNP
Positiona
(bp)
Haplotype
No. of
Homozygous
SNPsb
No.
of
SNPsc
Lengthd
(kb)
Affected Individuals
of Family A
Unaffected
Parents of
Individuals
11 and 14 Map Position
7 8 11 14 3 4 Marshﬁeld Cytogenetic
rs2108389 3542590 BB BB BB BB AB BB 12.15 p13.3 1 1 0
rs1384936 5374643 AA AA AA AA AB AB 19.73 p13.3 1 2 0
rs639251 5913530 BB BB BB BB BB AB 20.51 p13.3 1 3 0
rs2241393 6636304 AA AA AA AA AA AA 21.99 p13.3 1 4 0
rs164022 6779040 BB BB BB BB AB BB 22.34 p13.3 1 5 8.83
rs1862456 8829549 BB AB AB AB AB AA 30.48 p13.2 0 0 0
rs2112527 9464751 AB AB AA AA AA AA 32.66 p13.2 0 0 0
rs2009518 9660655 BB AB AB AB BB AB 32.78 p13.2 0 0 0
NOTE.—Alleles A and B are shown for each chromosome 19 SNP.
a On the physical map.
b SNPs that shared homozygosity in all the affected individuals are indicated as 1.
c Score of the sequential homozygous SNPs (the number of SNPs in the homozygous block).
d Length of the shared homozygosity interval.
the Excel software was generated to calculate the length
of the intervals of homozygosity and to score them ac-
cording to the number of SNPs within each interval that
shared homozygosity in all the affected individuals; the
ﬁrst homologous SNP got a score of 1, the second SNP got
a score of 2, and so on (table 3). Regions that demonstrated
a shared haplotype for at least two SNP markers in an
interval of at least 1 Mb for all the affected individuals
were further analyzed. Narrowing the number of the “sus-
pected” regions was done by genotyping two of the par-
ents (under the assumption that the disease-associated lo-
cus would show a shared homozygous haplotype in the
affected individuals but not in their parents).
Approximately 260 regions of homozygosity (a mini-
mum of two SNPs in a 11-Mb region) were found to be
shared by all four affected individuals. Analysis of 10K SNP
arrays of two obligate carrier parents (ﬁg. 1, individuals 3
and 4 of family A, parents of individuals 11 and 14) re-
duced the number of “suspect” loci, demonstrating that
only two of those regions were not homozygous in the
obligate carriers (12 SNPs in a 11-Mb region). One of these
loci was excluded using microsatellite markers (data not
shown). The second locus, on chromosome 19p13, con-
tained ﬁve SNPs in an ∼8.8-Mb interval between the telo-
meric end and rs164022 (table 3). The interval of homo-
zygosity was conﬁrmed by testing DNA samples of all the
affected individuals and 12 unaffected members of the
extended family, with use of additional markers within
the interval (D19S886, D19S1166, D19S247, D19S894,
D19S549, D19S177, D19S427, and D19S905) (table 1).
All the obligate carriers were shown to be heterozygous
for the haplotype, whereas none of the unaffected family
members was homozygous at this haplotype. Further de-
tailed mapping of the LCCS3 locus was performed using
21 microsatellite markers. Thirteen microsatellite markers
were selected from public genome databases (D19S886,
D19S1166, D19S247, D19S120, D19S424, D19S894,
D19S216, D19S549, D19S177, D19S1034, D19S427,
D19S905, and D19S391) (table 1). Eight novel microsat-
ellite markers were planned using the Tandem Repeats
Finder program and the UCSC Genome Browser data-
base (ch19_AAAT2, ch19_GT, ch19_AAAG, ch19_CTTT,
ch19_ATTC, Ch19_GAAT, ch19_CTAT, and ch19_TTCC) (ta-
ble 1). On the basis of this ﬁne mapping, the LCCS3 locus
was narrowed to 3.4 Mb on chromosome 19p13 between
markers D19S1116 and ch19_CTAT in family A (ﬁg. 3) and
in a second, unrelated Bedouin family (family B). Two-
point linkage analysis demonstrated a maximum LOD
score of at (table 4).Z p 3.9 vp 0.0max
Selection of Candidate Genes in the LCCS3 Interval
Of ∼120 positional candidate genes in the 3.4-Mb LCCS3
locus, 30 were fully sequenced. Genes selected to be se-
quenced (table 5) were those previously known to be ex-
pressed in the spinal cord and to participate in neuroge-
nesis or known to encode proteins that function in the
Figure 3. Linkage results for chromosome 19 for a partial pedigree of family A. The haplotype showing the homozygosity region is
boxed. Arrows indicate crossing-over events. The upper and lower boundaries were determined according to individuals 14 and 8,
respectively.
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Table 4. Two-Point LOD-Score Analysis of Family A for 12 Markers on Chromosome 19p13 with Use of
SUPERLINK
Marker
ID
Marker
Name
LOD at vp
.00 .01 .05 .10 .20 .30 .40
1 D19S886 5.185850 2.469052 1.816745 1.352973 .735673 .414711 .198239
2 D19S1166 9.036289 .117788 1.129059 1.282851 1.004234 .558832 .207434
3 D19S247 3.155144 3.068566 2.724091 2.300226 1.495462 .794720 .273807
4 D19S894 2.013806 1.973064 1.800441 1.570383 1.098154 .658975 .293541
5 D19S216 1.727720 1.690233 1.538654 1.346473 .962532 .600143 .279878
6 D19S549 .720431 .695902 .601303 .491581 .303699 .160810 .061703
7 D19S177 3.122706 3.046224 2.738937 2.353873 1.596748 .895484 .325370
8 D19S1034 3.303153 3.222378 2.896683 2.486550 1.677683 .935451 .350451
9 D19S427 3.522624 3.436507 3.090021 2.654764 1.797075 1.008254 .381538
10 Ch19CTAT 3.932675 3.840282 3.466661 2.992051 2.034242 1.128878 .420811
11 Ch19TTCC 1.153815 .163561 .373562 .502131 .455395 .303296 .144084
12 D19S905 8.280259 2.263770 .386081 .258759 .556117 .437770 .194493
NOTE.—LOD scores 11.0 are shown in bold.
Table 5. Candidate Genes in the LCCS3
Interval
Position
(bp) Gene
Type of DNA
Sequenceda
3581182 PIP5K1C C
3701771 APBA3 C
3831672 ATCAY C
3996217 ZBTB7 C
4041322 MAP2K2 C
4125106 SIRT6 C
4198087 Q7LE05 C
4229598 NP_064594.2 C
4255668 FSD1 C
4275041 STAP2 C
4294551 Q9Y2P1 C
4311368 SH3GL1 C
4396009 UBXD1 C
4493600 SEMA6B C
4590530 NP_689575.1 C
4608559 CS010 C
4789354 M6PRBP1 C
5157379 PTPRS C
5406442 ZNRF4 C
5509185 PLAC2 C
5538010 SAFB2 C
5629433 NP_991330.1 C
5774818 NRTN C
5781798 FUT6 G
5793902 FUT3 G
5817612 FUT5 G
5865219 CAPS C
5867158 RANBP3 C
6163966 MLLT1 C
6257725 ASAH3 C
NOTE.—The candidate genes in the interval were
arranged in the table by their location on the chro-
mosome, according to the Map Viewer, build 36, and
the UCSC Genome Browser.
a G indicates that genomic DNA was sequenced. C
indicates that cDNA was sequenced.
neural system (such as SEMA6B, PTPRS, and NRTN). An-
other group of candidates were genes known to be asso-
ciated with vesicle transport, such as SH3GL1, M6PRBP1,
and PIP5K1C. No mutation was found in any of those
genes, except PIP5K1C.
Identiﬁcation of the PIP5K1C Mutation
A G757A missense mutation (ﬁg. 4A) was identiﬁed in
exon 7 of PIP5K1C, encoding phosphatidylinositol-4-
phosphate 5-kinase, type I, gamma (PIPKIg). PIPKIg is an
enzyme that phophorylates PI4P to generate phosphati-
dylinositol-4,5-bisphosphate (PIP2).
18,19
The GrA mutation in PIP5K1C abolishes a TaqI restric-
tion site. Restriction-analysis screening for the mutation
was performed for all available family members. The mu-
tation segregated with the disease in 16 affected and un-
affected individuals in extended families A and B (ﬁg. 4B)
and was not detected in 340 alleles of unrelated Bedouin
individuals (data not shown). The mutation causes an as-
partic acidrasparagine substitution at amino acid 253
(D253N). The aspartic acid at position 253 is conserved
among other PIPK proteins and among species, from hu-
man to Saccharomyces cerevisiae, as can be seen in the
ConSeq results (ﬁg. 5A). The aspartic acid in position 253
is located in the PIPK domain within a conserved DLKGS
motif (ﬁg. 5B).
Kinase Activity of the Recombinant PIP5K1C Protein
To test whether the mutation had a functional effect on
the kinase activity of the PIPKIg protein, recombinant
wild-type and mutant proteins were generated. Mutant
and native full-length cDNA samples of PIP5K1C were RT-
PCR ampliﬁed from ﬁbroblasts of affected individuals and
healthy controls, respectively. The cDNA samples were
cloned into pGEX plasmids, and frame and sequence were
veriﬁed. Recombinant proteins were generated and afﬁn-
ity puriﬁed. Kinase-activity assay was performed using
PI4P as a substrate and [g32P]ATP. The labeled PIP2 product
was separated using thin-layer chromatography. Analysis
of kinase activity of normal and mutant recombinant
PIP5K1C proteins showed that the D253N mutation re-
duced the PIP5K1C kinase activity to barely detectable
levels (ﬁg. 5C). The mutation abrogates the kinase activity,
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Figure 4. The G757A mutation in exon 7 of PIP5K1C. A, Sequence analysis of the ArG substitution in an unaffected individual,
obligate carrier, and affected individual. chr p Chromosome. B, PIP5K1C exon 7 mutation scanned with TaqI restriction enzyme, with
schematic diagram illustrating the Taq1 fragments. C, Mutation analysis of family A members. PCR ampliﬁcation products were digested
with Taq1 restriction enzyme and were separated on 2% agarose gel. C p unrelated healthy control. Individuals 7, 8, 11, and 14 were
homozygous for the mutated allele. Individuals 1, 3, 4, 6, 12, and 13 were heterozygous for the wild-type and mutated alleles. Individuals
2 and 5 were homozygous for the wild-type allele.
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Figure 5. The D253N PIP5K1C mutation in LCCS3, which abolishes the PIP5K1C kinase activity. A, Prediction of the structural and
functional importance of the aspartic acid residue at position 253, done using the ConSeq server. The ConSeq conservation grade was
9 (highly conserved). B, The aspartic acid at position 253, which is within a conserved DLKGS motif in the PIPK domain of the PIP5K1C
protein. C, Puriﬁed wild-type (WT) and mutant (M) recombinant GST-PIP5K1C fusion proteins (SDS-PAGE). D, Kinase activity of wild-
type (WT) and mutant (M) PIP5K1C recombinant proteins, tested in a reaction mixture containing PI4P (80 mM) as substrate and
[g32P]ATP. The labeled PIP2 product was separated using thin-layer chromatography and was quantiﬁed by phosphor-imaging analysis.
PIP2 (meanSD of three independent experiments) synthesized by mutant recombinant PIP5K1C was 1.7%0.56% of PIP2 synthesized
by equal amount of wild-type PIP5K1C. GST p glutathione S-transferase (negative control).
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regardless of varying substrate concentrations—in tests of
the enzymatic activity of recombinant PIP5K1C at sub-
strate (PI4P) concentrations of 20 mM versus 30, 50, 100,
and 200 mM, the activity of the native enzyme was sig-
niﬁcantly augmented at higher substrate concentrations
(nearly 1,000-fold at the highest PI4P concentration),
whereas the enzymatic activity of the mutant PIP5K1C
was unaltered and remained nearly undetectable (data not
shown).
Discussion
We describe a novel arthrogryposis phenotype, LCCS3,
that is identical to LCCS2 except for the absence of a neu-
rogenic bladder. Genomewide linkage analysis of four af-
fected individuals from three branches of a single inbred
consanguineous kindred yielded ∼260 candidate loci. In-
terestingly, analysis of two obligate carrier parents of af-
fected individuals was extremely effective in narrowing
the number of candidate loci to two.
A homozygous PIP5K1C missense mutation (G757A)
was found in LCCS3-affected individuals. PIP5K1C is a
member of the type I PIPKIg family of enzymes that phos-
phorylates the ﬁfth hydroxyl of PI4P to generate PIP2. Al-
though both PIP5K types I and II enzymes synthesize PIP2,
type I PIP kinases account for the majority of PIP2 syn-
thesis. The type I PIP5K family includes three catalytically
active homologues: PIP5Ka, PIP5Kb, and PIP5Kg (also
called “PIP5K1A,” “PIP5K1B,” and “PIP5K1C,” respec-
tively). Of these three homologues, PIP5Kg is thought to
be the main enzyme responsible for PIP2 synthesis in the
brain.20,21 The aspartic acid at position 253 of PIP5Kg is
located in the catalytic core domain (PIPK domain) within
a DLKGS motif. Both the DLKGS motif and the aspartic
acid in this motif are well conserved among other PIPK
proteins and among species (from human to S. cerevisiae).
Mutation of Asp216 in the DLKGS domain of PIPKIIb was
shown to abolish its activity.22 Similarly, we show that the
Asp253Asn mutation found in the DLKGS domain of
PIP5Kg in LCCS3-affected patients signiﬁcantly reduced
the kinase activity of PIP5Kg to barely detectable levels,
regardless of substrate concentration. The human disease
caused by a homozygous defect in PIP5K1C is reminiscent
of the phenotype of the null mutants of its mouse ortho-
logue; PIPKg/ mice die within the 1st day of life. Al-
though no major developmental defects are observed in
these mice, their impaired mobility and inability to feed
after birth strongly suggest the occurrence of major neu-
rological defects.20 Low PIP2 concentrations have been
demonstrated in neurons of Pipkg/ mice,20 in line with
the defective PIP2 synthesis we demonstrate in human
LCCS3.
PIP2 plays an essential role in clathrin-dependent en-
docytosis of synaptic vesicle proteins: impairment of PIP2
hydrolysis results in the accumulation of clathrin-coated
vesicles, suggesting that the membrane concentration of
PIP2 controls the stability of endocytic clathrin coats.
23 In
yeast, PI3K-induced PIP2 depletion blocks endocytosis
23;
ex vivo, neurons of Pipkg/ mice demonstrate defects in
synaptic transmission, endocytic delay, and changes sug-
gestive of exocytic defects.20 Thus, it is plausible that the
LCCS3 arthrogryposis phenotype caused by inactivation
of PIP5K1C leading to low PIP2 levels results in defective
synaptic vesicle trafﬁcking, which incurs neuronal mal-
function. It should also be noted that both PIP2 and syn-
taxin are essential for exocytosis and that efﬁcient soluble
N-ethylmaleimide–sensitive factor attachment protein re-
ceptor (SNARE)–dependent fusion requires the generation
of PIP2.
24,25 This is in line with the fact that ARC, another
arthrogryposis syndrome, is caused by mutations in the
VPS33B gene,4 which encodes a Sec1/Munc-18 protein be-
longing to a subfamily of class C vacuolar sorting proteins
(VPS).4,26 VPS proteins are essential for intracellular
membrane-fusion reactions and are associated with severe
vacuolar protein–sorting and –morphology defects.27
We have shown28(in this issue) that LCCS2 is caused by a
mutation in ERBB3. ERBB3, known to heterodimerizewith
ERBB2, is involved in activating the PI3K pathway, which
leads to phosphorylation of PIP2 and to generation of
phosphatidylinositol-3,4,5-triphosphate (PIP3).
29–31 Since
the LCCS2 and LCCS3 phenotypes are very similar, it is
plausible that at least part of the defect seen in LCCS3 is
caused by diminished synthesis of PIP3, as a result of re-
duced synthesis of its precursor, PIP2.
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